Development and Feasibility of a Nurse-led Person-centered Education Program
Launched by SCHOOL OF HEALTH SCIENCES GENEVA · Jan 26, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
1. Introduction 1.1. Background and rationale Psoriasis is a systemic, immune-mediated disorder, characterized by inflammatory skin and joint manifestations that affects patient's quality of life, especially on a psychological, body aesthetic and social level, and therefore can impair not only their treatment adherence and sustainability of treatment but also patient-health care professional relationships. The psoriasis prevalence in adults in Europe ranges from 2% to 3%. If these findings are applied to the Swiss context it would mean that there are an estimated 180\'000 persons suffer...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed cutaneous psoriasis, regardless of the stage of the disease and treatment type (systemic and/or topic, and/or puva therapy)
- • Age over 18 years
- • Proficiency in the French language
- Exclusion Criteria:
- • Valid informed consent is not or cannot be given
- • Patients unable to follow the 6-session therapeutic education program
- • Patients currently engaged in any other therapeutic education program
About School Of Health Sciences Geneva
The School of Health Sciences Geneva is a leading academic institution dedicated to advancing healthcare through innovative research and education. With a strong emphasis on interdisciplinary collaboration, the School engages in clinical trials that aim to explore and enhance health outcomes across diverse populations. Committed to ethical standards and scientific rigor, the School fosters an environment that encourages the development of new therapies and health interventions, ultimately contributing to the global body of knowledge in health sciences. Through partnerships with clinical practitioners and research organizations, the School of Health Sciences Geneva is at the forefront of addressing pressing health challenges and improving patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lausanne, Vd, Switzerland
Patients applied
Trial Officials
Sebastian E Probst, Prof
Principal Investigator
University of Applied Sciences and Arts Western Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials